ArticleFrontline gastroenterology2022

Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab.

Charles Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.